"We're just starting to look at what the options and opportunities might be for selling the site," a Pfizer spokesman tells GlobeSt.com. "We plan to be out at the end of 2008. We'll still have a pretty significant presence in Kalamazoo."
The life sciences complex has 28 buildings related to research, development and pharmaceutical. The space breakdown is 720,000 sf of offices, 750,000 sf of laboratory and other research space and a 234,000-sf manufacturing facility. The complex is being offered for sale as a whole, or can be subdivided as a multitenant facility. Spaces in the 100,000-sf range and more are available for consideration.
The spokesman says the company does not have a number yet for what it expects to get in payment for the site. "Our hope is that we can find someone who can fully use the site." He says the company wants to help minimize the impact on the local area. "We fully recognize the pain of this decision, and are doing everything we can to work with the community," he says.
The community has already put together a massive campaign, Pfizer Strategic Working Action Teams, to aid the planned displaced workers, and has brought together more than 100 local economic development, business, educational, non-profit and government experts to plan how to handle the closings. One of the five main strategies that the SWAT teams are working on includes the immediate and efficient use of Pfizer's vacated offices, laboratories, production capabilities and auxiliary facilities.
Staubach managing principal Martin Horner will lead the team, along with Jay Koster and Michael Hochanadel from the company's Capital Markets as well as Chris Skibinski from the Industrial Division and Life Science Practice Group. Dave MacDonald, a principal with the company, will provide support.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.